tirzepatide fda shortage update says the weight-loss drug is over Important Announcement FDA Update on

doi: 10.1016/j.biopha.2023.115568 47 RodovalhoVRLuzBSRRabahHdo CarmoFLRFoladorELNicolasAet al

Oral GLP-1 medicines can cause side effects, often involving the stomach or digestion

Creatine is not metabolized by the liver or kidneys in a way that would interfere with tirzepatide's mechanism, which operates through GLP-1 receptor signaling in the brain and pancreas

H.NeuferP

Fewer tools to investigate compounded drugs During a 2018 inspection of a Dallas-area drug marketer, BioTE Medical, the FDA discovered undisclosed records of 4,202 adverse events linked to compounded hormone pellets

The intestinal immunoendocrine axis: novel cross-talk between enteroendocrine cells and the immune system during infection and inflammatory disease